National Health Service (NHS) UK

We recently announced a two-part collaboration with the UK Government-led clinical drug development initiative.



The initiative features a novel model created by the NOCRI to streamline the approach to undertaking clinical development in the UK with a single point of entry into the UK health system. This reduces complexity and increases the speed and efficiency of running drug development programs.

This collaboration enables us to benefit from the NIHR's new translational research infrastructure, their ability to set-up and deliver studies, and access to well characterized cohorts of patients from within the National Health Service. Teva will invest approximately $20 million in clinical development in the UK and up to an additional $1 million for basic research into dementia.